Literature DB >> 3942054

Amiodarone for refractory atrial fibrillation.

R L Gold, C I Haffajee, G Charos, K Sloan, S Baker, J S Alpert.   

Abstract

Atrial fibrillation (AF) is a difficult arrhythmia to manage with antiarrhythmic agents. Amiodarone is highly effective in restoring and maintaining normal sinus rhythm in patients with AF. However, the mechanism and predictors of efficacy for amiodarone in treating AF have not been adequately addressed. Various measures of success or failure of amiodarone therapy were examined in 68 patients who had paroxysmal or chronic, established AF refractory to conventional antiarrhythmic agents. The patients were 25 to 75 years old (mean 59) and mean follow-up was 21 months (range 3 to 56). Maintenance amiodarone dosages were 200 to 400 mg/day. Overall, amiodarone therapy was effective long term in 54 of the 68 patients (79%). Left atrial diameter, age, gender and origin of AF were not helpful in predicting success or failure of amiodarone therapy. The presence of chronic AF for longer than 1 year was an adverse factor in maintaining normal sinus rhythm (p = 0.007), although the success rate even in this group was relatively high (57%). Thirty-five percent of the patients had adverse effects, which precluded long-term therapy with amiodarone in 10%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942054     DOI: 10.1016/0002-9149(86)90964-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

Review 1.  Which patient should be referred to an electrophysiologist: supraventricular tachycardia.

Authors:  Richard J Schilling
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  Atrial fibrillation begets trouble.

Authors:  J E Waktare; A J Camm
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

3.  Long-term sinus rhythm maintenance after cardioversion of persistent atrial fibrillation: is the treatment's success predictable?

Authors:  Dariusz A Kosior; Marcin Szulc; Grzegorz Opolski; Adam Torbicki; Daniel Rabczenko
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

4.  The drug treatment of atrial fibrillation.

Authors:  K S Channer
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 5.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 6.  Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown.

Authors:  George E Blake; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2008-09-16

Review 7.  Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.

Authors:  S Lévy
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 8.  Low-dose amiodarone should not be the first-line treatment for atrial fibrillation.

Authors:  R J Sung
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 9.  Optimal management of older patients with atrial fibrillation.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

10.  Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.

Authors:  H J Crijns; A T Gosselink; K I Lie
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.